A possible role of antihypertensive polar renomedullary lipid (APRL) and prostaglandin E2 in the kidney in the antihypertensive action of pindolol.
The influence of the pretreatment with CV-3988, a specific antagonist of antihypertensive polar renomedullary lipid (APRL), and/or indomethacin on the antihypertensive effect of pindolol was examined in order to clarify a possible role of APRL and prostaglandin E2 (PGE2) in the kidney in the effect of pindolol in male spontaneously hypertensive rats (SHR). CV-3988 effectively attenuated the antihypertensive effect of pindolol, although pindolol still significantly lowered blood pressure following CV-3988 treatment. Besides, the pretreatment with CV-3988 showed no significant effect on an increased PGE2 level and a decreased volume of urine after pindolol treatment. The antihypertensive effect of pindolol disappeared after the CV-3988 treatment in combination with indomethacin.
D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D015232:Dinoprostone; D004573:Electrolytes / Q000652:urine; D007213:Indomethacin / Q000494:pharmacology; D007668:Kidney / Q000502:physiology*; D008297:Male; D010742:Phospholipid Ethers; D010869:Pindolol / Q000494:pharmacology*; D010972:Platelet Activating Factor / Q000031:analogs & derivatives* / Q000502:physiology; D011458:Prostaglandins E / Q000502:physiology*; D051381:Rats; D011918:Rats, Inbred SHR; D013844:Thiazoles / Q000494:pharmacology
D000959:Antihypertensive Agents; D004573:Electrolytes; D010742:Phospholipid Ethers; D010972:Platelet Activating Factor; D011458:Prostaglandins E; D013844:Thiazoles; C037145:1-hexadecyl-2-acetyl-glycero-3-phosphocholine; C037913:CV 3988; D010869:Pindolol; D015232:Dinoprostone; D007213:Indomethacin